86 research outputs found
Additional file 1: of Tumor necrosis factor receptor 1 (TNFRI) for ventilator-associated pneumonia diagnosis by cytokine multiplex analysis
Electronic supplement material. (DOC 702Â kb
Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations
<div><p>Bronchiectasis (BE) is a chronic and heterogeneous respiratory disease that requires a multidimensional scoring system to properly assess severity. The aim of this study was to compare the severity stratification by 2 validated scores (BSI and FACED) in a BE cohort and to determine their predictive capacity for exacerbations and hospitalizations. Moreover, we proposed a modified version of FACED which was created to better predict the risk of exacerbations in clinical practice. We performed a prospective cohort study including BE patients >18 years old with a follow-up period of 1-year. One-hundred eighty-two patients (40% males; mean age 68) were studied. Patients were stratified according to the number of exacerbations during the follow-up, and according to BSI and FACED scores. BSI classified most of our patients as severe 99 (54.4%) or moderate 47 (25.8%), while FACED mainly classified as mild 108 (59.3%) or moderate 61 (33.5%). BSI and FACED showed an area under ROC curve (AUC) for exacerbations of 0.808 and 0.734; and for hospitalizations (due to BE exacerbations) of 0.893 and 0.809, respectively. Subsequently, we modified FACED by adding previous exacerbations (Exa-FACED) and this new score classified patients as mild 48.4%, moderate 34.6% and severe 17.0%, with an improved AUC for exacerbations (0.760) and hospitalizations (0.820). Despite previous validations of BSI and FACED, they classified our patients very differently. As expected, FACED showed poor prognostic capacity for exacerbations. We support the Exa-FACED score to predict the risk future exacerbations for been easy to use in clinical practice.</p></div
Study flow diagram.
<p>Abbreviations: AECOPD: chronic obstructive pulmonary disease exacerbation.</p
The relative risks, absolute relative risks and number needed to harm of the events (mortality in the follow-up period at30 days, 6 months, 1 year and 3 years).
<p>The relative risks, absolute relative risks and number needed to harm of the events (mortality in the follow-up period at30 days, 6 months, 1 year and 3 years).</p
Significant univariate and multivariate Cox regression analyses predicting the probability of a 30-day readmission.
<p>Significant univariate and multivariate Cox regression analyses predicting the probability of a 30-day readmission.</p
Significant univariate and multivariate Cox regression analyses predicting the probability of death at 1 year.
<p>Significant univariate and multivariate Cox regression analyses predicting the probability of death at 1 year.</p
General characteristics of patients lost to follow-up (1 year follow-up).
<p>General characteristics of patients lost to follow-up (1 year follow-up).</p
- …